Real-world study confirms Entyvio's safety for ulcerative colitis patients
NCT ID NCT03824561
First seen Nov 01, 2025 · Last updated Jun 14, 2026 · Updated 26 times
Summary
This study looked at the long-term safety and effectiveness of the drug Entyvio (vedolizumab) in over 1,100 people with moderate to severe ulcerative colitis. Participants received the drug as part of their regular care, and researchers tracked side effects and how well the treatment worked. The goal was to understand how the drug performs in everyday medical practice, not just in controlled research settings.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ULCERATIVE COLITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Takeda Selected Site
Tokyo, Japan
Conditions
Explore the condition pages connected to this study.